中国肺癌杂志2026，Vol.29Issue(4)：310-314,5.DOI:10.3779/j.issn.1009-3419.2026.101.09
奥希替尼治疗后继发SCLC转化和ALK融合的EGFR突变型肺腺癌1例
A Case of EGFR-mutant Lung Adenocarcinoma with Secondary SCLC Transformation and ALK Fusion after Osimertinib Treatment
廖丽燕 1李小红1
作者信息
- 1. 410011 长沙,中南大学湘雅二医院病理科
- 折叠
摘要
Abstract
Epidermal growth factor receptor(EGFR)gene mutations are the most common driver mutations in non-small cell lung cancer(NSCLC).This article reports a case of a patient with EGFR-sensitive mutant lung adenocarcinoma who developed secondary transformation to small cell lung cancer(SCLC)and anaplastic lymphoma kinase(ALK)gene fu-sion following first-line Osimertinib therapy.This paper reported a case of concurrent SCLC transformation and ALK fusion occurring after Osimertinib treatment,suggesting that the two can coexist as dual drug resistance mechanisms.Re-biopsy com-bined with genetic testing is essential for identifying drug resistance mechanisms and guiding individualized therapy.关键词
肺肿瘤/表皮生长因子受体/间变性淋巴瘤激酶/小细胞肺癌转化/奥希替尼Key words
Lung neoplasms/Epidermal growth factor receptor/Anaplastic lymphoma kinase/Small cell lung can-cer transformation/Osimertinib引用本文复制引用
廖丽燕,李小红..奥希替尼治疗后继发SCLC转化和ALK融合的EGFR突变型肺腺癌1例[J].中国肺癌杂志,2026,29(4):310-314,5.
